vs
Side-by-side financial comparison of JBG SMITH Properties (JBGS) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.
Protagonist Therapeutics, Inc is the larger business by last-quarter revenue ($170.6M vs $127.6M, roughly 1.3× JBG SMITH Properties). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs -35.7%, a 112.9% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs -2.5%).
JBG SMITH PropertiesJBGSEarnings & Financial Report
JBG SMITH Properties is a publicly traded real estate investment trust based in Bethesda, Maryland.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
JBGS vs PTGX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $127.6M | $170.6M |
| Net Profit | $-45.5M | $131.7M |
| Gross Margin | — | — |
| Operating Margin | -47.5% | 74.3% |
| Net Margin | -35.7% | 77.2% |
| Revenue YoY | -2.5% | 184.4% |
| Net Profit YoY | 24.0% | 381.7% |
| EPS (diluted) | $-0.76 | $2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $127.6M | — | ||
| Q3 25 | $123.9M | — | ||
| Q2 25 | $126.5M | — | ||
| Q1 25 | $120.7M | — | ||
| Q4 24 | $130.8M | $170.6M | ||
| Q3 24 | $136.0M | — | ||
| Q2 24 | $135.3M | — | ||
| Q1 24 | $145.2M | $255.0M |
| Q4 25 | $-45.5M | — | ||
| Q3 25 | $-28.6M | — | ||
| Q2 25 | $-19.2M | — | ||
| Q1 25 | $-45.7M | — | ||
| Q4 24 | $-59.9M | $131.7M | ||
| Q3 24 | $-27.0M | — | ||
| Q2 24 | $-24.4M | — | ||
| Q1 24 | $-32.3M | $207.3M |
| Q4 25 | -47.5% | — | ||
| Q3 25 | -27.5% | — | ||
| Q2 25 | -18.4% | — | ||
| Q1 25 | -44.7% | — | ||
| Q4 24 | -53.6% | 74.3% | ||
| Q3 24 | -22.4% | — | ||
| Q2 24 | -24.3% | — | ||
| Q1 24 | -30.1% | 80.9% |
| Q4 25 | -35.7% | — | ||
| Q3 25 | -23.1% | — | ||
| Q2 25 | -15.2% | — | ||
| Q1 25 | -37.9% | — | ||
| Q4 24 | -45.8% | 77.2% | ||
| Q3 24 | -19.8% | — | ||
| Q2 24 | -18.0% | — | ||
| Q1 24 | -22.2% | 81.3% |
| Q4 25 | $-0.76 | — | ||
| Q3 25 | $-0.48 | — | ||
| Q2 25 | $-0.29 | — | ||
| Q1 25 | $-0.56 | — | ||
| Q4 24 | $-0.70 | $2.01 | ||
| Q3 24 | $-0.32 | — | ||
| Q2 24 | $-0.27 | — | ||
| Q1 24 | $-0.36 | $3.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $75.3M | $418.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $675.3M |
| Total Assets | $4.4B | $744.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.3M | — | ||
| Q3 25 | $64.4M | — | ||
| Q2 25 | $61.4M | — | ||
| Q1 25 | $81.3M | — | ||
| Q4 24 | $145.8M | $418.9M | ||
| Q3 24 | $137.0M | — | ||
| Q2 24 | $163.5M | — | ||
| Q1 24 | $220.5M | $322.6M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.8B | $675.3M | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.1B | $560.4M |
| Q4 25 | $4.4B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.7B | — | ||
| Q4 24 | $5.0B | $744.7M | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $5.3B | — | ||
| Q1 24 | $5.4B | $629.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.3M | $184.2M |
| Free Cash FlowOCF − Capex | — | $182.8M |
| FCF MarginFCF / Revenue | — | 107.1% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $101.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.3M | — | ||
| Q3 25 | $8.9M | — | ||
| Q2 25 | $18.8M | — | ||
| Q1 25 | $12.9M | — | ||
| Q4 24 | $129.4M | $184.2M | ||
| Q3 24 | $26.4M | — | ||
| Q2 24 | $23.8M | — | ||
| Q1 24 | $37.0M | $-27.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $182.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-27.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 107.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -10.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
